MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

CP-105696

CAS No. : 158081-99-3

MCE 站：CP-105696

产品活性：CP-105696 是一个有效的、白三烯 B₄ (LTB₄) 受体的选择性拮抗剂，其 IC₅₀ 值为 8.42 nM。

研究领域：GPCR/G Protein

作用靶点：Leukotriene Receptor

In Vitro: CP-105696 is a structurally novel, selective and potent LTB₄ receptor antagonist. In vitro, CP-105696 inhibits [³H]LTB₄ (0.3 nM) binding to high-affinity LTB₄ receptors on human neutrophils with an lC₅₀ value of 8.42±0.26 nM. Scatchard analyses of [³H]LTB₄ binding to these high-affinity receptors indicate that CP-105696 acts as a noncompetitive antagonist. CP-105696 inhibits human neutrophil chemotaxis mediated by LTB₄ (5 nM) in a noncompetitive manner with an IC₅₀ value of 5.0±2.0 nM. Scatchard analyses of [³H]LTB₄ binding to low-affinity receptors on neutrophils indicate that CP-105696 acts as a competitive antagonist at this receptor, and inhibition of LTB₄-mediated CD11b upregulation on human neutrophils is competitively inhibited by CP-105696 (pA₂=8.03±0.19). CP-105696 at 10 μM does not inhibit either human neutrophil chemotaxis or CD11b upregulation mediated through alternate (i.e., C5a, lL-8, PAF) G-protein coupled chemotactic factor receptors. In isolated human monocytes, LTB₄ (5 nM)-mediated Ca²⁺ mobilization is inhibited by CP-105696 with an lC₅₀ value of 940±70 nM.

In Vivo: At a dose of 50 mg/kg/day (28 days), B10.BR (H2k) allografts transplanted into C57Bl/6 (H2b) recipients are significantly protected, as reflected by the mean survival time versus control grafts (27±20 days [n=10] vs. 12±6 days [n=14]; P=0.0146). Using an induction protocol (day -1 to day 3), CP-105696 at 100 mg/kg/day significantly prolongs allograft survival (33±23 days [n=9]; P=0.0026), but CP-105696 at 10 mg/kg/day does not (18±16 days [n=8]; P=0.1433). Syngeneic grafts survive indefinitely (n=11). Immunohistological evaluation of allografts at rejection reveals a mononuclear cell infiltrate composed primarily of CD3+ and CD11b+ (Mac-1+) cells, which are infrequent in syngeneic grafts. Allografts from mice treated with CP-105696 at 50 or 100 mg/kg/day demonstrat a selective reduction in β2-integrin (Mac-1) expression on monocytes/macrophages, as demonstrated by CD11b staining density compared with allograft controls.

相关产品：MK-571 sodium salt  |  Montelukast sodium  |  MK-886  |  Zafirlukast  |  Pranlukast  |  Nedocromil  |  LY223982  |  HAMI 3379  |  Leukotriene B4  |  LY255283  |  (S)-Verapamil hydrochloride  |  5-O-Demethylnobiletin  |  BIIL-260 hydrochloride  |  Etalocib  |  11-?Keto-?beta-?boswellic acid  |  12S-HHT  |  AS-35  |  Darbufelone  |  KP496  |  RG-12525  |  Veliflapon  |  CP-96021 hydrochloride  |  LM-1484  |  Quinotolast sodium  |  RS-601

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。